26 September 2023
26 September 2023
Novartis has also obtained approvals to list Sandoz shares from regulatory authorities including the SIX Exchange Regulation.
The approval was based on data from the pivotal AReSVi-006 Phase III vaccine efficacy study.
Valo is eligible to receive potential milestone payments of $2.7bn for up to 11 programmes from Novo Nordisk.
The approval was based on data from the EPCORE NHL-1 Phase I/II multi-centre, single-arm, open-label trial.
Pierre Fabre will fund the discovery and development of multiple small-molecule cancer therapies.
Eisai and BioArctic’s Leqembi is the only approved treatment that slows cognitive and functional decline in adults with Alzheimer’s.
Mentions of AI in relation to the pharmaceutical sector reached a peak in Q3 2023.
There are several anti-TNF therapies on the market for the treatment of rheumatoid arthritis, which include AbbVie’s anti-TNF Humira (adalimumab).
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Despite challenging business conditions in 2021 and 2022, large CMOs were still involved in acquisitions to enhance their capabilities or scale of production. Catalent and Recipharm were particularly active in acquiring companies during this period, and these acquisitions had a focus on advanced biologic capabilities related to cell and gene therapies. CMOs are increasingly targeting companies with sophisticated (biologic and specialized) capabilities to manufacture modern drugs and seek high-value contracts.
Give your business an edge with our leading industry insights.
